LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: The addition of the sFlt-1/PlGF ratio to the protein/creatinine ratio in multiple pregnancy: Post-hoc analysis of the PREPARE cohort study.

    Wind, M / Dekker, L / van den Akker-van Marle, M E / Ballieux, B E P B / Cobbaert, C M / Rabelink, T J / van Lith, J M M / Teng, Y K O / Sueters, M

    Pregnancy hypertension

    2024  Volume 36, Page(s) 101111

    Abstract: Objective: To assess the predictive accuracy of the sFlt-1/PlGF ratio cut-off 38 in addition to the standard-of-care spot urine protein/creatinine ratio (PCr) for multiple pregnancies in women with suspected pre-eclampsia.: Study design: Post-hoc ... ...

    Abstract Objective: To assess the predictive accuracy of the sFlt-1/PlGF ratio cut-off 38 in addition to the standard-of-care spot urine protein/creatinine ratio (PCr) for multiple pregnancies in women with suspected pre-eclampsia.
    Study design: Post-hoc analysis of a prospective cohort study.
    Main outcome measures: Primary outcome was the occurrence of pre-eclampsia in one and four weeks after presentation with suspected pre-eclampsia. Test characteristics with 95% confidence intervals (CI) were calculated on pre-eclampsia development in one and four weeks.
    Results: Twenty-three multiple pregnancies with suspected pre-eclampsia between 20 and 37 weeks gestation were included for analysis. Women who eventually developed pre-eclampsia had a significantly higher PCr (34.0 vs. 16.5, p = 0.015), sFlt-1 (17033 vs. 5270 pg/ml, p = 0.047) and sFlt-1/PlGF ratio (99 vs. 25, p = 0.033) at baseline. Furthermore, PCr ≥ 30 and sFlt-1/PlGF ratio > 38 was respectively seen in 1/16 (6.3 %) and 3/16 (18.8 %) of the women who did not develop pre-eclampsia. For predicting pre-eclampsia within one week the sFlt-1/PlGF ratio sensitivity was 75.0 % [95 % CI 19.4-99.4] and the negative predictive value 93.8 % [73.0-98.8], while no pre-eclampsia developed when PCr was < 30. Consequently, the combination of these tests did not lead to an improvement in test characteristics, with non-significant differences in positive predictive value (50.0 % [29.5-70.5] versus 80.0 % [37.3-96.4]) compared to PCr alone for pre-eclampsia development in one week.
    Conclusions: In addition to standard-of-care spot urine PCr measurements, this study has not been able to demonstrate that the sFlt-1/PlGF ratio cut-off 38 is of added value in the prediction of pre-eclampsia in multiple pregnancy.
    Trial registration: Netherlands Trial Register (NL8308).
    Language English
    Publishing date 2024-02-21
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2584464-7
    ISSN 2210-7797 ; 2210-7789
    ISSN (online) 2210-7797
    ISSN 2210-7789
    DOI 10.1016/j.preghy.2024.101111
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Therapeutic plasma exchange in pregnancy: A literature review.

    Wind, M / Gaasbeek, A G A / Oosten, L E M / Rabelink, T J / van Lith, J M M / Sueters, M / Teng, Y K O

    European journal of obstetrics, gynecology, and reproductive biology

    2021  Volume 260, Page(s) 29–36

    Abstract: Therapeutic plasma exchange (TPE) is indicated as a treatment for a wide array of diseases, extensively addressed in the Guidelines of the American Society for Apheresis. In pregnancy, TPE is an uncommon event and application is largely based on ... ...

    Abstract Therapeutic plasma exchange (TPE) is indicated as a treatment for a wide array of diseases, extensively addressed in the Guidelines of the American Society for Apheresis. In pregnancy, TPE is an uncommon event and application is largely based on extrapolation of efficacy and safety in a non-pregnant population. This review intends to describe the currently available experience of TPE in pregnancy to help clinicians recognise indications during pregnancy and to support current guideline recommendations with literature-based experiences. In order to identify the clinical indications for which TPE is applied in pregnant women, we performed a literature search including studies till November 2019, without a start date restriction. Data extraction included medical indication for TPE and safety of TPE in pregnant women. 279 studies were included for analysis. Nowadays, TPE is predominantly applied for thrombotic microangiopathies, lipid disorders and a variety of autoimmune diseases. The application of TPE during pregnancy remains largely empiric and relies on individual case reports in the absence of high-quality studies and definitive evidence-based guidelines. Safety profile of TPE during pregnancy appears to be comparable to application of TPE in non-pregnant patients. In conclusion, based on the limited evidence that we found in literature with a high risk of publication bias, TPE procedures can be used safely during pregnancy with the appropriate preparation and experience of a multidisciplinary team.
    MeSH term(s) Autoimmune Diseases/therapy ; Blood Component Removal ; Female ; Humans ; Plasma Exchange ; Pregnancy ; Retrospective Studies ; Thrombotic Microangiopathies
    Language English
    Publishing date 2021-03-03
    Publishing country Ireland
    Document type Journal Article ; Review
    ZDB-ID 190605-7
    ISSN 1872-7654 ; 0301-2115 ; 0028-2243
    ISSN (online) 1872-7654
    ISSN 0301-2115 ; 0028-2243
    DOI 10.1016/j.ejogrb.2021.02.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical value and cost analysis of the sFlt-1/PlGF ratio in addition to the spot urine protein/creatinine ratio in women with suspected pre-eclampsia: PREPARE cohort study.

    Wind, M / van den Akker-van Marle, M E / Ballieux, B E P B / Cobbaert, C M / Rabelink, T J / van Lith, J M M / Teng, Y K O / Sueters, M

    BMC pregnancy and childbirth

    2022  Volume 22, Issue 1, Page(s) 910

    Abstract: Background: This study investigated the clinical value of adding the sFlt-1/PlGF ratio to the spot urine protein/creatinine ratio (PCr) in women with suspected pre-eclampsia.: Methods: This was a prospective cohort study performed in a tertiary ... ...

    Abstract Background: This study investigated the clinical value of adding the sFlt-1/PlGF ratio to the spot urine protein/creatinine ratio (PCr) in women with suspected pre-eclampsia.
    Methods: This was a prospective cohort study performed in a tertiary referral centre. Based on the combination of PCr (< 30) and sFlt-1/PlGF (≤38) results, four groups were described: a double negative result, group A-/-; a negative PCr and positive sFlt-1/PlGF, group B-/+; a positive PCr and negative sFlt-1/PlGF, group C+/-; and a double positive result, group D+/+. The primary outcome was the proportion of false negatives of the combined tests in comparison with PCr alone in the first week after baseline. Secondary, a cost analysis comparing the costs and savings of adding the sFlt-1/PlGF ratio was performed for different follow-up scenarios.
    Results: A total of 199 women were included. Pre-eclampsia in the first week was observed in 2 women (2%) in group A-/-, 12 (26%) in group B-/+, 4 (27%) in group C+/-, and 12 (92%) in group D+/+. The proportion of false negatives of 8.2% [95% CI 4.9-13.3] with the PCr alone was significantly reduced to 1.6% [0.4-5.7] by adding a negative sFlt-1/PlGF ratio. Furthermore, the addition of the sFlt-1/PlGF ratio to the spot urine PCr, with telemonitoring of women at risk, could result in a reduction of 41% admissions and 36% outpatient visits, leading to a cost reduction of €46,- per patient.
    Conclusions: Implementation of the sFlt-1/PlGF ratio in addition to the spot urine PCr, may lead to improved selection of women at low risk and a reduction of hospital care for women with suspected pre-eclampsia.
    Trial registration: Netherlands Trial Register (NL8308).
    MeSH term(s) Female ; Humans ; Pre-Eclampsia/diagnosis ; Cohort Studies ; Prospective Studies ; Netherlands ; Costs and Cost Analysis
    Language English
    Publishing date 2022-12-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 2059869-5
    ISSN 1471-2393 ; 1471-2393
    ISSN (online) 1471-2393
    ISSN 1471-2393
    DOI 10.1186/s12884-022-05254-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Regression of HIV-associated grade IV T cell lymphoma with combined antiretroviral therapy only.

    Teng, Y K O / Schippers, E F / Wijermans, P W

    International journal of hematology

    2011  Volume 93, Issue 6, Page(s) 811–814

    Abstract: The present report describes repeated long-term remissions of a high-grade T cell lymphoma in an HIV-positive patient upon cART only, without additional chemotherapy. A review of cases from the literature further illustrates the anti-tumor effects of ... ...

    Abstract The present report describes repeated long-term remissions of a high-grade T cell lymphoma in an HIV-positive patient upon cART only, without additional chemotherapy. A review of cases from the literature further illustrates the anti-tumor effects of cART through the induction of a strong immune reconstitution in HIV-infected patients.
    MeSH term(s) Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Bone and Bones/pathology ; CD4 Lymphocyte Count ; HIV Infections/complications ; Humans ; Lymphoma, AIDS-Related/diagnosis ; Lymphoma, AIDS-Related/drug therapy ; Lymphoma, AIDS-Related/pathology ; Lymphoma, T-Cell/diagnosis ; Lymphoma, T-Cell/drug therapy ; Lymphoma, T-Cell/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Positron-Emission Tomography ; Tomography, X-Ray Computed ; Treatment Outcome ; Viral Load
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2011-05-11
    Publishing country Japan
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 1076875-0
    ISSN 1865-3774 ; 0917-1258 ; 0925-5710
    ISSN (online) 1865-3774
    ISSN 0917-1258 ; 0925-5710
    DOI 10.1007/s12185-011-0859-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Diagnosis and treatment of C3 glomerulopathy in a center of expertise.

    Koopman, J J E / Teng, Y K O / Boon, C J F / van den Heuvel, L P / Rabelink, T J / van Kooten, C / de Vries, A P J

    The Netherlands journal of medicine

    2019  Volume 77, Issue 1, Page(s) 10–18

    Abstract: C3 glomerulopathy is a rare renal disease that has been distinguished as a renal disease for about 10 years. It is caused by an excessive activation of the alternative complement pathway in the circulation, which leads to deposition of complement factor ... ...

    Abstract C3 glomerulopathy is a rare renal disease that has been distinguished as a renal disease for about 10 years. It is caused by an excessive activation of the alternative complement pathway in the circulation, which leads to deposition of complement factor C3 in glomeruli. It is diagnosed based on clinical presentation, histological patterns in a kidney biopsy and tests of the complement pathways. It can closely resemble immune complexmediated glomerulonephritis and postinfectious glomerulonephritis. Renal failure develops in up to half of all patients within 10 years after presentation. A curative treatment is not available. Treatment relies on renoprotective measures, occasional immunosuppressive medication and experimental novel complement inhibitors. Because the disease is rare, its care and cure are concentrated in centers of expertise. Here we provide an overview of the state-ofthe-art diagnosis and treatment of C3 glomerulopathy in a center of expertise in the Netherlands.
    MeSH term(s) Complement Activation/physiology ; Complement C3/metabolism ; Complement Pathway, Alternative/immunology ; Complement Pathway, Alternative/physiology ; Glomerulonephritis/diagnosis ; Glomerulonephritis/drug therapy ; Glomerulonephritis/immunology ; Humans ; Kidney/pathology ; Kidney Glomerulus/metabolism ; Kidney Glomerulus/pathology
    Chemical Substances C3 protein, human ; Complement C3
    Language English
    Publishing date 2019-02-17
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 193149-0
    ISSN 1872-9061 ; 0300-2977
    ISSN (online) 1872-9061
    ISSN 0300-2977
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Azathioprine-induced eosinophilic myocarditis in a patient with ANCA-associated vasculitis.

    Berden, Annelies E / Beeres, Saskia L M A / Crobach, Stijn / Schalij, Martin J / Rabelink, Ton J / Teng, Y K O

    Clinical and experimental rheumatology

    2016  Volume 34, Issue 3 Suppl 97, Page(s) S146

    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Azathioprine/adverse effects ; Eosinophilia/chemically induced ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Myocarditis/chemically induced ; Ventricular Function, Left/drug effects
    Chemical Substances Immunosuppressive Agents ; Azathioprine (MRK240IY2L)
    Language English
    Publishing date 2016-05
    Publishing country Italy
    Document type Case Reports ; Letter
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A breathtaking DRESS due to amoxicillin-clavulanate presenting as polymorphic eruption of the pregnancy.

    van Kester, M S / Langeveld, T J C / Bouwsma, H / van Rees, J B / Holman, E R / Teng, Y K O / van Zuuren, E J

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2018  Volume 32, Issue 12, Page(s) e436–e437

    MeSH term(s) Adult ; Amoxicillin-Potassium Clavulanate Combination/adverse effects ; Anti-Bacterial Agents/adverse effects ; Cardiac Tamponade/etiology ; Diagnosis, Differential ; Drug Hypersensitivity Syndrome/diagnosis ; Drug Hypersensitivity Syndrome/etiology ; Female ; Humans ; Lung Diseases, Interstitial/chemically induced ; Myocarditis/chemically induced ; Pregnancy ; Pregnancy Complications/diagnosis ; Pruritus/diagnosis
    Chemical Substances Anti-Bacterial Agents ; Amoxicillin-Potassium Clavulanate Combination (74469-00-4)
    Language English
    Publishing date 2018-05-03
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.14956
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.

    Groot, N / Shaikhani, D / Teng, Y K O / de Leeuw, K / Bijl, M / Dolhain, R J E M / Zirkzee, E / Fritsch-Stork, R / Bultink, I E M / Kamphuis, S

    Arthritis & rheumatology (Hoboken, N.J.)

    2018  Volume 71, Issue 2, Page(s) 290–301

    Abstract: Objective: Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long-term outcome data are limited. This study was undertaken to identify clinical characteristics and health-related quality of life ( ... ...

    Abstract Objective: Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long-term outcome data are limited. This study was undertaken to identify clinical characteristics and health-related quality of life (HRQoL) of adults with childhood-onset SLE.
    Methods: Patients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI-2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed.
    Results: In total, 111 childhood-onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI-2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease-modifying antirheumatic drugs. The vast majority of new childhood-onset SLE-related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI-2K score ≥8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively).
    Conclusion: The majority of adults with childhood-onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug-free remission, illustrating the substantial impact of childhood-onset SLE on future life.
    MeSH term(s) Adolescent ; Adult ; Age of Onset ; Aged ; Antibodies, Antiphospholipid/immunology ; Antirheumatic Agents/therapeutic use ; Child ; Child, Preschool ; Female ; Glucocorticoids/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use ; Hypertension/epidemiology ; Kidney Transplantation/statistics & numerical data ; Logistic Models ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/epidemiology ; Lupus Erythematosus, Systemic/immunology ; Lupus Nephritis/epidemiology ; Lupus Nephritis/surgery ; Lupus Vasculitis, Central Nervous System/epidemiology ; Male ; Middle Aged ; Multivariate Analysis ; Musculoskeletal Diseases/epidemiology ; Myocardial Infarction/epidemiology ; Netherlands/epidemiology ; Odds Ratio ; Prednisone/therapeutic use ; Quality of Life ; Severity of Illness Index ; Stroke/epidemiology ; Young Adult
    Chemical Substances Antibodies, Antiphospholipid ; Antirheumatic Agents ; Glucocorticoids ; Hydroxychloroquine (4QWG6N8QKH) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2018-11-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.40697
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Diagnosing and treating antiphospholipid syndrome: a consensus paper.

    Limper, M / de Leeuw, K / Lely, A T / Westerink, J / Teng, Y K O / Eikenboom, J / Otter, S / Jansen, A J G / V D Ree, M / Spierings, J / Kruyt, N D / van der Molen, R / Middeldorp, S / Leebeek, F W G / Bijl, M / Urbanus, R T

    The Netherlands journal of medicine

    2019  Volume 77, Issue 3, Page(s) 98–108

    Abstract: Introduction: The antiphospholipid syndrome (APS) is defined by the occurrence of venous and/or arterial thrombosis and/or pregnancy-related morbidity, combined with the presence of antiphospholipid antibodies (aPL) and/or a lupus anticoagulant (LAC). ... ...

    Abstract Introduction: The antiphospholipid syndrome (APS) is defined by the occurrence of venous and/or arterial thrombosis and/or pregnancy-related morbidity, combined with the presence of antiphospholipid antibodies (aPL) and/or a lupus anticoagulant (LAC). Large, controlled, intervention trials in APS are limited. This paper aims to provide clinicians with an expert consensus on the management of APS.
    Methods: Relevant papers were identified by literature search. Statements on diagnostics and treatment were extracted. During two consensus meetings, statements were discussed, followed by a Delphi procedure. Subsequently, a final paper was written.
    Results: Diagnosis of APS includes the combination of thrombotic events and presence of aPL. Risk stratification on an individual base remains challenging. 'Triple positive' patients have highest risk of recurrent thrombosis. aPL titres > 99th percentile should be considered positive. No gold standard exists for aPL testing; guidance on assay characteristics as formulated by the International Society on Thrombosis and Haemostasis should be followed. Treatment with vitamin K-antagonists (VKA) with INR 2.0-3.0 is first-line treatment for a first or recurrent APS-related venous thrombotic event. Patients with first arterial thrombosis should be treated with clopidogrel or VKA with target INR 2.0-3.0. Treatment with direct oral anticoagulants is not recommended. Patients with catastrophic APS, recurrent thrombotic events or recurrent pregnancy morbidity should be referred to an expert centre.
    Conclusion: This consensus paper fills the gap between evidence-based medicine and daily clinical practice for the care of APS patients.
    MeSH term(s) 4-Hydroxycoumarins/therapeutic use ; Anticoagulants/therapeutic use ; Antiphospholipid Syndrome/complications ; Antiphospholipid Syndrome/diagnosis ; Antiphospholipid Syndrome/therapy ; Delphi Technique ; Female ; Humans ; Indenes/therapeutic use ; Pregnancy ; Pregnancy Complications/diagnosis ; Pregnancy Complications/immunology ; Pregnancy Complications/therapy ; Thrombosis/immunology ; Thrombosis/therapy ; Vitamin K/antagonists & inhibitors ; Vitamin K/therapeutic use
    Chemical Substances 4-Hydroxycoumarins ; Anticoagulants ; Indenes ; antivitamins K ; Vitamin K (12001-79-5)
    Language English
    Publishing date 2019-04-23
    Publishing country Netherlands
    Document type Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 193149-0
    ISSN 1872-9061 ; 0300-2977
    ISSN (online) 1872-9061
    ISSN 0300-2977
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: CD20 epitope masking by rituximab: comment on the article by Gunnarsson et al.

    Teng, Y K O / Ioan-Facsinay, A / van Laar, Jacob M

    Arthritis and rheumatism

    2008  Volume 58, Issue 2, Page(s) 634; author reply 634

    MeSH term(s) Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Murine-Derived ; Antirheumatic Agents/immunology ; Antirheumatic Agents/pharmacology ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; Epitopes/immunology ; Humans ; In Vitro Techniques ; Rituximab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Murine-Derived ; Antirheumatic Agents ; Epitopes ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2008-02
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 127294-9
    ISSN 1529-0131 ; 0004-3591 ; 2326-5191
    ISSN (online) 1529-0131
    ISSN 0004-3591 ; 2326-5191
    DOI 10.1002/art.23298
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top